Results from 45% of Clinical Trials are kept Secret
A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the…
A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the…
After a promising kick off, Novartis is raising doubts about the future of its CAR-T…
GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company's CFO, who…
CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off…
Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs…
Dublin-based Inflazome has made a splashy debut by closing Series A with €15M. The company…
A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA…
MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis…
MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase…
These are the best results yet for CAR-T, this time from a research group led by…
CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes…
Pretty impressive CAR-T news coming from across the Channel... Oxford BioMedica just launched a second…